Jaguar Health, Inc.: Update on Its Nasdaq Listing Status

Jaguar Health, Inc. (NASDAQ: JAGX) recently informed the public of its current status regarding its listing on the Nasdaq. The company is appealing a potential delisting of its securities from the Nasdaq, and a hearing is scheduled, announced Lisa Conte, President and CEO of Jaguar. Jaguar's stock will continue to trade under the symbol 'JAGX' during the appeal process. Jaguar's management remains committed to complying with Nasdaq listing standards.

In May 2023, Jaguar was warned by Nasdaq of noncompliance due to its stock price remaining below the required minimum of $1 for 30 consecutive days. A grace period was granted until May 6, 2024, to regain compliance. On February 15, 2024, a letter indicating a violation of the "Minimum Bid Price Rule" was received, leading to a potential delisting on February 26, 2024, unless an appeal is requested.

Furthermore, Jaguar is continuing the analysis of data from the phase 3 clinical trial OnTarget for crofelemer, a plant-derived drug, in the prevention of chemotherapy-induced diarrhea. Crofelemer is extracted from the bark of Croton lechleri, with a sustainable harvesting program.

The Jaguar Health family of companies is focused on developing prescription plant-based medicines for gastrointestinal disorders in humans and animals. Milan-based Napo Therapeutics aims to expand access to crofelemer in Europe.